with our observations in patients after kidney transplantation. PGE1 lessened the risk of DGF in our patients by 10-15%.
Recently, Polyak and co-workers found in extended criteria donor kidneys, that PGE1 reduces the incidence of DGF and enhances perfusion characteristics during continuous hypothermic pulsatile perfusion [6 ] . In this group with a very high risk of DGF, PGE1 was superior to trifluoperazine and verapamil. The PGE1 effect on DGF reached significance in this high risk group with 25 patients in each group.
Regarding our data, we would need a prospective study with 239 patients in each group with a statistical power of 90% to show a significant effect for nonselected kidney donors [7] . Furthermore, the PGE1 effect on long-term graft survival has to be determined. 1995; 9: 282-288 This pilot study shows an encouraging benefit of a centres to whom we sent kidneys.
Prophylaxe des akuten Nierenversagens in der suprarenalen
In previous studies of patients with normal renal Aortenchirurgie. Zentralbl Chir 1993; 118: 390-394 function, PGE1 was shown to decrease the incidence Although MMF is widely used in children post-transplant, pharmacokinetic data for MPA in this time. This discrepancy can be attributed to a 35% decline (P<0.01) of the free MPA fraction from 1.4% patient population are scarce and dosage guidelines are therefore preliminary.
(range 0.6-5.1%) in the initial phase post-transplant to 0.9% (range 0. values increased 2-fold from 32.4 (range ically best predictive of the clinical immunosuppressive 13.9-57.0) mg×h/l at 3 weeks to 65.1 (range efficacy of MMF, these findings may have con-32.6-114) mg×h/l at 3 months after grafting, whereas sequences for the dosing recommendations of MMF in renal transplant recipients. the AUC 0-12 values of free MPA did not change over Nephrol Dial Transplant (1999) 
